A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK plus in NSCLC

被引：0
|
作者：
Chen, Xianguo [1 ]
Xu, Bo [1 ]
Fu, Fangni [2 ]
Cai, Ke [2 ]
Yu, Zhaonan [2 ]
机构：
[1] Zhejiang Univ, Jinhua Hosp, Dept Thorac Surg, Jinhua 330700, Zhejiang, Peoples R China
[2] Hangzhou DA Med Lab, Hangzhou 310030, Peoples R China
来源：
LUNG CANCER | 2021年 / 158卷
关键词：
D O I：
10.1016/j.lungcan.2021.05.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：162 / 163
页数：2
相关论文
共 50 条
  • [41] Is Retention of the 5′ Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC
    Hsiao, Susan J.
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (07) : 1103 - 1105
  • [42] Identification of Novel ALK Translocation in Gynecologic Clear Cell Carcinoma
    Yang, Chen
    Love-Gregory, Latisha
    Zhang, Lingxin
    Hagemann, Ian
    Cao, Dengfeng
    MODERN PATHOLOGY, 2019, 32
  • [43] Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy
    Malighetti, Federica
    Villa, Matteo
    Sala, Elisa
    Sharma, Geeta
    Arosio, Giulia
    Gemelli, Maria
    Manfroni, Chiara
    Fontana, Diletta
    Cordani, Nicoletta
    Meneveri, Raffaella
    Zambon, Alfonso
    Piazza, Rocco
    Pagni, Fabio
    Cortinovis, Diego
    Mologni, Luca
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Identification of Novel ALK Translocation in Gynecologic Clear Cell Carcinoma
    Yang, Chen
    Love-Gregory, Latisha
    Zhang, Lingxin
    Hagemann, Ian
    Cao, Dengfeng
    LABORATORY INVESTIGATION, 2019, 99
  • [45] Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination
    Urbanska, E. M.
    Melchior, L. C.
    Sorensen, J. B.
    Santoni-Rugiu, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S645 - S646
  • [46] Advanced ALK plus NSCLC New Follow-up Data on 3rd Generation ALK-TKI
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06)
  • [47] Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC
    Schmid, S.
    Chotai, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1088
  • [48] Lorlatinib for ALK plus NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
    Ng, R.
    Zuraik, C.
    On, P. V.
    Khoudigian, S.
    Sharma, A.
    Peloquin, F.
    Aita, F. Fanton
    Rupp, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S450 - S450
  • [49] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [50] Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH
    Hutarew, Georg
    Hauser-Kronberger, Cornelia
    Strasser, Felix
    Llenos, Ida C.
    Dietze, Otto
    HISTOPATHOLOGY, 2014, 65 (03) : 398 - 407
12345